Bristol evaluates Vanlev
Executive Summary
Bristol-Myers Squibb is reviewing "all relevant options" regarding the future of antihypertensive Vanlev (omapatrilat) following "disappointing news" from FDA's Cardiovascular & Renal Drugs Advisory Committee, CEO Peter Dolan says July 23. The committee said the drug would need a trial in highly refractory patients and a risk management program to support approval (1"The Pink Sheet" July 22, p. 20). "We are currently reviewing the committee discussions, following up with FDA to better understand the agency's point of view and evaluating all relevant options"...